188 related articles for article (PubMed ID: 22120090)
1. Pharmacokinetics, pharmacodynamics and safety of tolvaptan, a novel, oral, selective nonpeptide AVP V2-receptor antagonist: results of single- and multiple-dose studies in healthy Japanese male volunteers.
Kim SR; Hasunuma T; Sato O; Okada T; Kondo M; Azuma J
Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S5-17. PubMed ID: 22120090
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of oral tolvaptan administered in 15- to 60-mg single doses to healthy Korean men.
Yi S; Jeon H; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
J Cardiovasc Pharmacol; 2012 Apr; 59(4):315-22. PubMed ID: 22130104
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of single-dose oral tolvaptan in fasted and non-fasted states in healthy Caucasian and Japanese male subjects.
Shoaf SE; Kim SR; Bricmont P; Mallikaarjun S
Eur J Clin Pharmacol; 2012 Dec; 68(12):1595-603. PubMed ID: 22585285
[TBL] [Abstract][Full Text] [Related]
4. Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects.
Shoaf SE; Bricmont P; Mallikaarjun S
Br J Clin Pharmacol; 2012 Apr; 73(4):579-87. PubMed ID: 21988334
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects.
Shoaf SE; Wang Z; Bricmont P; Mallikaarjun S
J Clin Pharmacol; 2007 Dec; 47(12):1498-507. PubMed ID: 17925589
[TBL] [Abstract][Full Text] [Related]
6. Effect of grapefruit juice on the pharmacokinetics of tolvaptan, a non-peptide arginine vasopressin antagonist, in healthy subjects.
Shoaf SE; Mallikaarjun S; Bricmont P
Eur J Clin Pharmacol; 2012 Feb; 68(2):207-11. PubMed ID: 21853290
[TBL] [Abstract][Full Text] [Related]
7. Phase III clinical pharmacology study of tolvaptan.
Inomata T; Izumi T; Matsuzaki M; Hori M; Hirayama A;
Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S57-65. PubMed ID: 22120094
[TBL] [Abstract][Full Text] [Related]
8. Effects of tolvaptan on volume overload in Japanese patients with heart failure: results of a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Matsuzaki M; Hori M; Izumi T; Asanoi H; Tsutamoto T;
Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S19-31. PubMed ID: 22120091
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide.
Shoaf SE; Bramer SL; Bricmont P; Zimmer CA
J Cardiovasc Pharmacol; 2007 Aug; 50(2):213-22. PubMed ID: 17703139
[TBL] [Abstract][Full Text] [Related]
10. Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure.
Onogawa T; Sakamoto Y; Nakamura S; Nakayama S; Fujiki H; Yamamura Y
Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S67-76. PubMed ID: 22120095
[TBL] [Abstract][Full Text] [Related]
11. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.
Costello-Boerrigter LC; Smith WB; Boerrigter G; Ouyang J; Zimmer CA; Orlandi C; Burnett JC
Am J Physiol Renal Physiol; 2006 Feb; 290(2):F273-8. PubMed ID: 16189291
[TBL] [Abstract][Full Text] [Related]
12. Oral V2 receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind, placebo-controlled, single ascending dose study.
Thuluvath PJ; Maheshwari A; Wong F; Yoo HW; Schrier RW; Parikh C; Steare S; Korula J
Aliment Pharmacol Ther; 2006 Sep; 24(6):973-82. PubMed ID: 16948809
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study).
Matsuzaki M; Hori M; Izumi T; Fukunami M;
Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S33-45. PubMed ID: 22120092
[TBL] [Abstract][Full Text] [Related]
14. Serum and urine responses to the aquaretic agent tolvaptan in hospitalized hyponatremic patients.
Vaghasiya RP; DeVita MV; Michelis MF
Int Urol Nephrol; 2012 Jun; 44(3):865-71. PubMed ID: 21607553
[TBL] [Abstract][Full Text] [Related]
15. Effect of vasopressin antagonism on renal handling of sodium and water and central and brachial blood pressure during inhibition of the nitric oxide system in healthy subjects.
Al Therwani S; Mose FH; Jensen JM; Bech JN; Pedersen EB
BMC Nephrol; 2014 Jun; 15():100. PubMed ID: 24965902
[TBL] [Abstract][Full Text] [Related]
16. Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men.
Ohnishi A; Orita Y; Okahara R; Fujihara H; Inoue T; Yamamura Y; Yabuuchi Y; Tanaka T
J Clin Invest; 1993 Dec; 92(6):2653-9. PubMed ID: 8254021
[TBL] [Abstract][Full Text] [Related]
17. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.
Gheorghiade M; Niazi I; Ouyang J; Czerwiec F; Kambayashi J; Zampino M; Orlandi C;
Circulation; 2003 Jun; 107(21):2690-6. PubMed ID: 12742979
[TBL] [Abstract][Full Text] [Related]
18. Effect of tolvaptan on renal water and sodium excretion and blood pressure during nitric oxide inhibition: a dose-response study in healthy subjects.
Al Therwani S; Rosenbæk JB; Mose FH; Bech JN; Pedersen EB
BMC Nephrol; 2017 Mar; 18(1):86. PubMed ID: 28288570
[TBL] [Abstract][Full Text] [Related]
19. Absolute bioavailability of tolvaptan and determination of minimally effective concentrations in healthy subjects.
Shoaf SE; Bricmont P; Mallikaarjun S
Int J Clin Pharmacol Ther; 2012 Feb; 50(2):150-6. PubMed ID: 22257581
[TBL] [Abstract][Full Text] [Related]
20. Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses.
Guo B; Wu X; Zhang Y; Shi Y; Yu J; Cao G; Zhang J
Clin Drug Investig; 2012 Jul; 32(7):475-86. PubMed ID: 22650326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
